GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.44 USD
-0.47 (-1.07%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $43.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Company Summary
GSK has three segments: Specialty Medicines (HIV, Oncology, Immunology/Respiratory and Other), Vaccines (Meningitis, Influenza, Shingles, RSV and Established Vaccines) and General Medicines (Respiratory and Other), which are clubbed as commercial operations.
In August 2019, GSK and Pfizer merged their consumer healthcare unit into a new joint venture (JV). GSK owned a controlling stake of 68% in the Consumer Healthcare JV.
However, on Jul 18, 2022, GSK de-merged its Consumer Healthcare (CHC) segment into a standalone company. The independent Consumer Healthcare company has been named Haleon. The company changed its name to GSK plc ...
Company Summary
GSK has three segments: Specialty Medicines (HIV, Oncology, Immunology/Respiratory and Other), Vaccines (Meningitis, Influenza, Shingles, RSV and Established Vaccines) and General Medicines (Respiratory and Other), which are clubbed as commercial operations.
In August 2019, GSK and Pfizer merged their consumer healthcare unit into a new joint venture (JV). GSK owned a controlling stake of 68% in the Consumer Healthcare JV.
However, on Jul 18, 2022, GSK de-merged its Consumer Healthcare (CHC) segment into a standalone company. The independent Consumer Healthcare company has been named Haleon. The company changed its name to GSK plc from GlaxoSmithKline plc in mid-May 2022.
GSK boasts a diversified base and presence in different geographical areas The company has made significant progress in expanding its presence in emerging markets by acquiring product portfolios from companies like Bristol-Myers and UCB. GSK’s new and specialty products are doing well and have become key drivers of top-line growth.
GSK is also divesting non-core assets. In 2015, GSK divested two quadrivalent meningitis ACWY vaccines – Nimenrix and Mencevax – to Pfizer, a portfolio of over-the-counter (OTC) brands to Perrigo, and all its remaining rights to Arzerra for auto-immune indications including multiple sclerosis to Novartis.
In 2019, GSK acquired Tesaro, an oncology-focused biotech company, which added the PARP inhibitor Zejula (approved for ovarian cancer) to its portfolio. In 2022, Glaxo acquired Sierra Oncology (which added Ojjaara (momelotinib) for myelofibrosis with anemia) and Affinivax (which added a next-generation 24-valent pneumococcal vaccine candidate). In 2023, GSK acquired Bellus Health, which added camlipixant, a phase III asset for refractory chronic cough.
Specialty Medicines, Vaccines and General Medicines segments contributed approximately 33.8%, 32.5% and approximately 33.7%, respectively, to revenues in 2023. Total sales in 2023 were £30.3 billion ($37.9 billion).
The company is headquartered in Brentford, UK.
General Information
GSK PLC Sponsored ADR
980 GREAT WEST ROAD
BRENTFORD, X0 TW8 9GS
Phone: 44-20-8047-5000
Fax: 44-20-8047-7807
Web: http://www.gsk.com
Email: gsk.investor-relations@gsk.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/6/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.22 |
Current Year EPS Consensus Estimate | 4.15 |
Estimated Long-Term EPS Growth Rate | 7.50 |
Exp Earnings Date | 11/6/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 43.91 |
52 Week High | 45.93 |
52 Week Low | 33.68 |
Beta | 0.66 |
20 Day Moving Average | 3,484,680.50 |
Target Price Consensus | 46.46 |
4 Week | 11.50 |
12 Week | 6.35 |
YTD | 18.48 |
4 Week | 2.38 |
12 Week | 0.93 |
YTD | 0.05 |
Shares Outstanding (millions) | 2,072.53 |
Market Capitalization (millions) | 91,004.75 |
Short Ratio | NA |
Last Split Date | 11/12/1991 |
Dividend Yield | 3.44% |
Annual Dividend | $1.51 |
Payout Ratio | 0.36 |
Change in Payout Ratio | -0.18 |
Last Dividend Payout / Amount | 8/16/2024 / $NA |
Fundamental Ratios
P/E (F1) | 10.58 |
Trailing 12 Months | 10.56 |
PEG Ratio | 1.42 |
vs. Previous Year | 12.37% |
vs. Previous Quarter | 0.00% |
vs. Previous Year | 10.72% |
vs. Previous Quarter | 6.53% |
Price/Book | 5.24 |
Price/Cash Flow | 8.47 |
Price / Sales | 2.30 |
6/30/24 | 51.48 |
3/31/24 | 51.54 |
12/31/23 | 51.45 |
6/30/24 | 11.41 |
3/31/24 | 11.01 |
12/31/23 | 10.57 |
6/30/24 | 0.82 |
3/31/24 | 0.87 |
12/31/23 | 0.88 |
6/30/24 | 0.54 |
3/31/24 | 0.58 |
12/31/23 | 0.62 |
6/30/24 | 21.46 |
3/31/24 | 21.31 |
12/31/23 | 20.74 |
6/30/24 | 12.87 |
3/31/24 | 14.62 |
12/31/23 | 16.24 |
6/30/24 | 16.02 |
3/31/24 | 17.97 |
12/31/23 | 20.00 |
6/30/24 | 8.39 |
3/31/24 | 8.09 |
12/31/23 | 7.74 |
6/30/24 | 1.56 |
3/31/24 | 1.55 |
12/31/23 | 1.57 |
6/30/24 | 0.99 |
3/31/24 | 1.15 |
12/31/23 | 1.19 |
6/30/24 | 49.65 |
3/31/24 | 53.39 |
12/31/23 | 54.30 |